Screening for liver fibrosis population based study across European countries
Liver cirrhosis is a very common and severe chronic disease, responsible for high morbidity, impaired quality of life, major healthcare costs, and poor survival, causing an estimated 170,000 deaths per year in Europe. Liver cirrho...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2021-125394OA-I00
ESTADIFICACION NO INVASIVA DE LA ESTETATOHEPATITIS NO ALCOHO...
121K€
Cerrado
LITMUS
Liver Investigation Testing Marker Utility in Steatohepatit...
47M€
Cerrado
mtFOIE GRAS
mitoFOIE GRAS Non invasive Profiling of Mitochondrial Funct...
455K€
Cerrado
RADIcAL
Non invasive rapid assessment of chronic liver disease using...
3M€
Cerrado
LIVERAIM
A Biomarker Based Platform for Early Diagnosis of Chronic Li...
25M€
Cerrado
FLIP
Fatty liver Inhibition of Progression
8M€
Cerrado
Información proyecto LiverScreen
Duración del proyecto: 66 meses
Fecha Inicio: 2019-12-12
Fecha Fin: 2025-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Liver cirrhosis is a very common and severe chronic disease, responsible for high morbidity, impaired quality of life, major healthcare costs, and poor survival, causing an estimated 170,000 deaths per year in Europe. Liver cirrhosis is preceded by a long period of slowly developing, asymptomatic, liver fibrosis; most commonly caused by non-alcoholic fatty liver disease (NAFLD, related to obesity and type 2 diabetes), alcohol, and hepatitis B or C virus infection. There is no treatment available to reverse advanced liver cirrhosis. However, if fibrosis could be detected early, all of the major causes are still amenable to prevention and treatment. Early diagnosis of liver fibrosis in the general population is therefore crucial for the estimated 10 million Europeans with undetected liver fibrosis.
The LiverScreen project aims to develop a targeted screening methodology to identify persons with asymptomatic liver fibrosis and cirrhosis among the general population. This methodology involves: 1) identification of groups from the general population at high risk of having chronic liver disease, 2) screening their liver stiffness with the innovative transient elastography (TE) technology (until now only validated in patients with known liver disease) for diagnosis, and 3) determining the right follow-up screening regime. Within the LiverScreen project 8 European countries will collaborate and perform research in over 34,000 subjects to develop the screening methodology and demonstrate its accuracy, clinical value, cost-effectiveness, acceptability, and potential to be implemented by healthcare systems throughout Europe.
Using the LiverScreen program, diagnosis at an early stage can stop liver disease progression and have a subsequent long-term impact on liver disease morbidity and mortality and the associated societal burdens in terms of economic costs and health inequity. The estimated cost reduction ranges from €850 to €4,000 per quality-adjusted life-year gained.